Cardiac allograft vasculopathy (CAV) is a pathologic immune-mediated remodelling of the
vasculature in transplanted hearts and, by impairing perfusion, is the major cause of late …

Abstract Aim The “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management
of Patients With Chronic Coronary Disease” provides an update to and consolidates new …

Cochrane, Maria Crespo Leiro, Anne Dipchand, Brian Feingold, Kathleen Grady, Edward
Horn, Maryl Johnson, Donna Mancini, Sean Pinney, Heather Ross, Kari Wujcik, Andreas …

Cardiac allograft vasculopathy remains a major limiting factor in the long-term survival of the
heart transplant recipient. Our understanding of its pathogenesis is continuously evolving as …

Significant practice-changing developments have occurred in the care of heart
transplantation candidates and recipients over the past decade. This Canadian …

This study investigated the effect of low‐dose aspirin in primary adult liver transplantation
(LT) on acute cellular rejection (ACR) as well as arterial patency rates. The use of low‐dose …

Perioperative Management of Heart Transplantation: A Clinical Review Page 1 CliniCal FoCus
Review ANESTHESIOLOGY, V 139 • NO 4 OcTObEr 2023 493 Perioperative Management of …

Cardiac allograft vasculopathy (CAV) is a complex disease that remains a significant cause
of morbidity and mortality after orthotopic heart transplantation (OHT). Originating as a result …

Aims Cardiac allograft vasculopathy (CAV) is the major long‐term complication after heart
transplantation, leading to mortality and re‐transplantation. As available non‐invasive …

Cardiac allograft vasculopathy (CAV) limits long‐term survival after heart transplantation.
Non‐invasive evaluation is challenging, and currently, there is no validated biomarker for …